{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:34:53Z","timestamp":1760150093399,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Chimeric antigen receptor T-cells (CAR-T) are now a standard approach for treating relapsed\/refractory B-cell lymphomas. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) is a newly described entity that can manifest following CAR-T. Bone marrow (BM) aplasia is an uncommon manifestation of IEC-HS reported after CAR-T-cell therapy and is defined as the reduction or absence of hematopoietic progenitor cells resulting in severe pancytopenia. We describe the case of a 44-year-old female with relapsed\/refractory Burkitt lymphoma (BL) who received treatment with lisocabtagene maraleucel with her post-CAR-T course complicated by cytokine release syndrome (CRS) and IEC-HS ultimately leading to persistent BM aplasia. She underwent a rescue allogeneic stem cell transplant but ultimately succumbed to progressive disease. IEC-HS is an increasingly recognized complication that occurs after CAR-T treatments that can result in aplasia, a dangerous complication with serious sequelae including infection, transfusion dependence, and high risk for hemorrhage. The underlying mechanism is poorly understood, and further studies are needed to understand how to treat it better.<\/jats:p>","DOI":"10.3390\/medsci11040067","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T12:46:13Z","timestamp":1697114773000},"page":"67","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed\/Refractory Burkitt\u2019s Lymphoma"],"prefix":"10.3390","volume":"11","author":[{"given":"Troy J.","family":"Kenkel","sequence":"first","affiliation":[{"name":"Department of General Internal Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nithya","family":"Sridhar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay R.","family":"Hammons","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5514-2903","authenticated-orcid":false,"given":"Maria","family":"Hintzke","sequence":"additional","affiliation":[{"name":"Department of Pathology & Laboratory Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4336-1071","authenticated-orcid":false,"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ganeeva, I., Zmievskaya, E., Valiullina, A., Kudriaeva, A., Miftakhova, R., Rybalov, A., and Bulatov, E. (2022). Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies. Bioengineering, 9.","DOI":"10.3390\/bioengineering9120808"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","article-title":"Burkitt\u2019s lymphoma","volume":"379","author":"Molyneux","year":"2012","journal-title":"Lancet"},{"key":"ref_4","first-page":"253","article-title":"Clinical and Epidemiological Characteristics of Burkitt Lymphomas in Pediatric Patients from Two Defined Socioeconomic Regions in Mexico","volume":"63","year":"2017","journal-title":"J. Trop. Pediatr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1080\/10428194.2022.2102625","article-title":"CAR T-cells in relapsed Burkitt lymphoma\u2014A promising test drive in a rare disease","volume":"63","author":"Haydu","year":"2022","journal-title":"Leukemia Lymphoma"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41409-018-0235-0","article-title":"Car T cells induce a complete response in refractory Burkitt lymphoma","volume":"53","author":"Avigdor","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.21037\/tcr-22-174","article-title":"Allogeneic car-T bridging to Allo-HSCT as a treatment strategy for refractory adult Burkitt\u2019s Lymphoma: A Case Report","volume":"11","author":"Cheng","year":"2022","journal-title":"Transl. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00432-020-03198-7","article-title":"Sequential anti-cd19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: A case report and literature review","volume":"146","author":"Du","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/bloodadvances.2021004557","article-title":"Sequential different B-cell antigen\u2013targeted car T-cell therapy for pediatric refractory\/relapsed Burkitt lymphoma","volume":"6","author":"Liu","year":"2022","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1080\/10428194.2022.2076853","article-title":"Durable remissions in two adult patients with Burkitt lymphoma following anti-cd19 car T-cell therapy: A single center experience","volume":"63","author":"Seitter","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"096368972199664","DOI":"10.1177\/0963689721996649","article-title":"Successful treatment of pediatric refractory Burkitt lymphoma PTLD after liver transplantation using Anti-CD19 chimeric antigen receptor T-cell therapy","volume":"30","author":"Wang","year":"2021","journal-title":"Cell Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"879983","DOI":"10.3389\/fimmu.2022.879983","article-title":"Chimeric antigen receptor-modified T cell immunotherapy for relapsed and refractory adult Burkitt lymphoma","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1182\/blood.2019002008","article-title":"Early response observed in pediatric patients with relapsed\/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells","volume":"135","author":"Zhang","year":"2020","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s00262-021-02850-6","article-title":"CAR19\/22 T cell therapy in adult refractory Burkitt\u2019s lymphoma","volume":"70","author":"Zhou","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood.2022017015","article-title":"Oligoclonal T-cell expansion in a patient with BM failure after CD19 CAR-T for Richter transformed DLBCL","volume":"140","author":"Rejeski","year":"2022","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Rejeski, K., Kunz, W.G., Rudelius, M., B\u00fccklein, V., Blumenberg, V., Schmidt, C., Karschnia, P., Sch\u00f6berl, F., Dimitriadis, K., and von Baumgarten, L. (2021). Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of BM aplasia after CD19-directed CAR T-cell therapy\u2014A case report. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-020-05755-4"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e002721","DOI":"10.1136\/jitc-2021-002721","article-title":"Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: A case report","volume":"9","author":"Baur","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"E89","DOI":"10.1002\/ajh.25725","article-title":"Allogenic hematopoietic stem cell transplantation for prolonged BM aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma","volume":"95","author":"Qasrawi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00277-022-04889-6","article-title":"Thrombopoietin receptor agonist for treating BM aplasia following anti-CD19 CAR-T cells-single-center experience","volume":"101","author":"Perry","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_20","unstructured":"Moore, C.A., and Krishnan, K. (2022). StatPearls, StatPearls Publishing."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1042819031000141301","article-title":"Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: Preserved efficacy with decreased toxicity","volume":"45","author":"Lacasce","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomization of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_25","first-page":"7571","article-title":"Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt Lymphoma","volume":"41","author":"Samples","year":"2023","journal-title":"Clin. Oncol."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/11\/4\/67\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:05:27Z","timestamp":1760130327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/11\/4\/67"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["medsci11040067"],"URL":"https:\/\/doi.org\/10.3390\/medsci11040067","relation":{},"ISSN":["2076-3271"],"issn-type":[{"type":"electronic","value":"2076-3271"}],"subject":[],"published":{"date-parts":[[2023,10,12]]}}}